Freshly Printed - allow 10 days lead
Couldn't load pickup availability
Treating Life-Threatening Bleedings
Development of Recombinant Coagulation Factor VIIa
Provides a detailed roadmap on the development of original ideas, also serving as a guide for the development of new coagulation products
Ulla Hedner (Author)
9780128124390, Elsevier Science
Paperback, published 6 July 2017
214 pages
22.9 x 15.1 x 1.5 cm, 0.36 kg
Treating Life-Threatening Bleedings: Development of Recombinant Coagulation Factor VIIa provides a comprehensive understanding of the first new drug within the area of hemostasis, describing a new mechanism of action that has resulted in a modified concept of the whole hemostasis mechanism. As the treatment of life-threatening bleedings is a serious challenge for clinicians, this powerful and historic case study presents a detailed roadmap on how a new medicine can be developed, stressing the interaction between science and clinical work. The book stresses the importance of patient care in the learning process and provides new ideas on how to approach diseases and their treatment. Users will find a real world example that will act as a timely resource for those learning about, or engaged in, performing and supervising research across the biomedical sciences.
1. Classical Bleeding Disease (Hemophilia)2. My Encounter With Hemophilia (1959-82)3. The First Years at Novo Nordisk4. The Development of Recombinant FVIIa (rFVIIa) (1985-88)5. The Further Use and Development of rFVIIa (1989-96)6. Legal Issues Regarding the Use of rFVIIa in Hemophilia Patients With Inhibitors7. Treatment With rFVIIa in Malmö (1996-99)8. The Launching and Uses of rFVIIa9. Mechanism of Action and Dosage10. The Continued Development of rFVIIa During the 2000s11. Safety and Health Economy of rFVIIa12. Three Different Descriptions of How rFVIIa Was Developed13. Some Final Remarks
Subject Areas: Haematology [MJF]
